General Information of DTT (ID: TTWG9A4)

DTT Name Adrenergic receptor alpha-2A (ADRA2A) DTT Info
Gene Name ADRA2A

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
4 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [2]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [3]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [4]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [5]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [6]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [7]
------------------------------------------------------------------------------------
7 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [8]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [9]
A-80426 DMBC3DG N. A. N. A. Terminated [10]
S-18616 DMQ8S4L Pain MG30-MG3Z Terminated [11]
SK&F-104078 DMRADBU N. A. N. A. Terminated [12]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [13]
WB-4101 DMQU8B1 N. A. N. A. Terminated [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Discontinued Drug(s)
67 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [15]
(1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol DMF6WHC Discovery agent N.A. Investigative [16]
(1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine DMPKM9B Discovery agent N.A. Investigative [17]
(1H-Imidazol-2-yl)-quinoxalin-6-yl-amine DMRDHL2 Discovery agent N.A. Investigative [17]
(2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine DM27TH9 Discovery agent N.A. Investigative [17]
(2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine DM8N79M Discovery agent N.A. Investigative [17]
(2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DME6MYZ Discovery agent N.A. Investigative [18]
(3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine DM5WJBH Discovery agent N.A. Investigative [18]
(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DMHED9G Discovery agent N.A. Investigative [18]
(R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DM98L2X Discovery agent N.A. Investigative [19]
(S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMS4JAG Discovery agent N.A. Investigative [19]
1',2',3',6'-Tetrahydro-[2,4']bipyridinyl DMFDK4N Discovery agent N.A. Investigative [20]
1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline DMDYX7P Discovery agent N.A. Investigative [21]
1,2,3,4,5,6-Hexahydro-benzo[c]azocine DMTKYFE Discovery agent N.A. Investigative [19]
1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol DMHKANE Discovery agent N.A. Investigative [22]
1,2,3,4-Tetrahydro-isoquinolin-7-ol DM5VLIE Discovery agent N.A. Investigative [22]
1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF Discovery agent N.A. Investigative [23]
1,2,3,4-tetrahydroisoquinoline DMZGCEQ Discovery agent N.A. Investigative [24]
1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP Discovery agent N.A. Investigative [25]
1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine DMWFU3T Discovery agent N.A. Investigative [20]
1-(pyridin-2-yl)piperazine DMKE7FG Discovery agent N.A. Investigative [20]
2,3,4,5-Tetrahydro-1H-benzo[c]azepine DM1RE9Q Discovery agent N.A. Investigative [19]
2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine DM4EZOB Discovery agent N.A. Investigative [19]
2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine DMOFG4M Discovery agent N.A. Investigative [19]
2,3-Dihydro-1H-isoindole DMWI9XS Discovery agent N.A. Investigative [19]
2-BFi DMFAW4R Discovery agent N.A. Investigative [26]
3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline DMDPUC7 Discovery agent N.A. Investigative [27]
3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline DMH1RX6 Discovery agent N.A. Investigative [16]
3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMIWQ7G Discovery agent N.A. Investigative [19]
3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline DMZY6VX Discovery agent N.A. Investigative [28]
4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH Discovery agent N.A. Investigative [6]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [29]
4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR Discovery agent N.A. Investigative [30]
4-Benzo[b]thiophen-4-yl-1H-imidazole DM02Q8N Discovery agent N.A. Investigative [31]
5-Aminomethyl-naphthalen-2-ol DMTP9DB Discovery agent N.A. Investigative [22]
6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene DMNOI7B Discovery agent N.A. Investigative [19]
7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 Discovery agent N.A. Investigative [32]
7-Nitro-1,2,3,4-tetrahydro-isoquinoline DMX3UV1 Discovery agent N.A. Investigative [28]
8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline DMY50UR Discovery agent N.A. Investigative [22]
AKUAMMIGINE DMJW4I5 Discovery agent N.A. Investigative [33]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [34]
Beta-methoxyamphetamine DMA9CSG Discovery agent N.A. Investigative [35]
BRL 44408 DM3WPO4 Discovery agent N.A. Investigative [36]
Butyl-indol-1-yl-pyridin-4-yl-amine DM1CX9Y Discovery agent N.A. Investigative [18]
C-(6-Methoxy-naphthalen-1-yl)-methylamine DMJ6SYI Discovery agent N.A. Investigative [22]
C-Naphthalen-1-yl-methylamine DMFW1JC Discovery agent N.A. Investigative [22]
Chloroethylclonidine DMKZIES Discovery agent N.A. Investigative [37]
Ciproxifan DM9N8WM Dementia 6D80-6D86 Investigative [38]
Ethyl-indol-1-yl-pyridin-4-yl-amine DM3CWFR Discovery agent N.A. Investigative [18]
GNF-PF-2857 DML5QFZ Discovery agent N.A. Investigative [39]
GNF-PF-3878 DM7BXHQ Discovery agent N.A. Investigative [39]
Indol-1-yl-methyl-pyridin-4-yl-amine DMJB876 Discovery agent N.A. Investigative [18]
Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine DMR9GNW Discovery agent N.A. Investigative [18]
Indol-1-yl-pyridin-4-yl-amine DM1F53L Discovery agent N.A. Investigative [18]
JP1302 DMMVBK6 Discovery agent N.A. Investigative [39]
METHYLNORADRENALINE DMOWMPL Discovery agent N.A. Investigative [14]
MEZILAMINE DMVYWJS Discovery agent N.A. Investigative [40]
PIPEROXAN DMIHO0P Discovery agent N.A. Investigative [14]
R-226161 DM4BP7S Discovery agent N.A. Investigative [41]
S-34324 DMZLQ5W Discovery agent N.A. Investigative [10]
SK&F-29661 DM2KFQ5 Discovery agent N.A. Investigative [28]
SK&F-64139 DM60Y3Q Discovery agent N.A. Investigative [24]
SNAP-5150 DM2OLGQ Discovery agent N.A. Investigative [13]
TRACIZOLINE DM18CV3 Discovery agent N.A. Investigative [32]
Tramazoline DM3ML0N Discovery agent N.A. Investigative [14]
TRYPTOLINE DMV19K7 Discovery agent N.A. Investigative [32]
[3H]RX821002 DM6IRN4 Discovery agent N.A. Investigative [42]
------------------------------------------------------------------------------------
⏷ Show the Full List of 67 Investigative Drug(s)
Molecule Interaction Atlas

References

1 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
4 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
5 Clinical pipeline report, company report or official report of Klus Pharma
6 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
9 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
10 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
11 S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1206-22.
12 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
13 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
14 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
15 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
16 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90.
17 Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23.
18 Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81.
19 Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46.
20 Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5.
21 N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.
22 Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005.
23 Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5.
24 Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33.
25 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
26 Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7.
27 3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40.
28 Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7.
29 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
30 Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24.
31 Alpha(2) adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethyl-6,7-dihydro-thianaphthene as a high-affini... J Med Chem. 2000 Apr 6;43(7):1423-6.
32 Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9.
33 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
34 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
35 Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
36 Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
37 Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70.
38 The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
39 Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
40 4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8.
41 Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
42 Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3.